Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout
Novo Nordisk made waves early last year after showing that its blockbuster diabetes drug was also highly effective at treating non-diabetic adults with obesity. But now Eli Lilly has fired a warning shot across Novo’s bow, putting forth its own set of obesity data for its experimental drug tirzepatide.
In a Phase III study comparing three dose levels of the drug to placebo, tirzepatide reduced patients’ weights by an average of 16%, 21.4% and 22.5% at the respective doses, compared to just 2.4% on placebo. Lilly did not report p-values for the study, but instead produced figures as “efficacy estimands,” which it said represented the efficacy prior to discontinuation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
